Cannabis Report
Lithium
Home > Boards > US OTC > Cannabis >

CV Sciences Inc. (CVSI)

CVSI RSS Feed
Add CVSI Price Alert      Hide Sticky   Hide Intro
Moderator: stock_observer_77, AsiaT, ANIA77, ap17, Sunblazers, Benjamin Wulf
Search This Board: 
Last Post: 8/16/2018 5:06:51 PM - Followers: 393 - Board type: Free - Posts Today: 124

CV Sciences United States OTCMKTS:CVSI Business Cannabidiol - united states

CV Sciences, Inc., incorporated on July 26, 2013, is a life science company. The Company operates in two segments: specialty pharmaceuticals and consumer products. The Company’s specialty pharma business segment is focused on developing and commercializing therapeutics utilizing synthetic Cannabidiol (CBD) across several therapeutic areas. The consumer product business segment is focused on manufacturing, marketing and selling plant-based CBD products to a range of market sectors.

 

The Company's product candidates utilize synthetic CBD as the active pharmaceutical ingredient. Its product candidates are in preclinical studies. The Company manufactures, markets and sells products containing hemp-derived CBD primarily under its PlusCBD brand. The Company's subsidiaries include US Hemp Oil, LLC, CannaVest Laboratories, LLC, Plus CBD, LLC and CannaVest Europe, GmbH.

The Company focuses on developing and commercializing proprietary prescription drugs utilizing synthetic cannabidiol (CBD) as the active pharmaceutical ingredient and is engaged in the development, manufacturing, marketing and sale of consumer products containing plant-based CBD, which is refined into its own proprietary branded products. CV Sciences initial drug candidate (CVSI-007) is a chewing gum that combines CBD and nicotine, which the Company believes has the potential to effectively treat smokeless tobacco use and addiction. The market for cessation of smokeless tobacco use and addiction is estimated at $2 billion, growing to over $4 billion in the next 5-6 years.

 

CV Sciences, Inc. Issues Letter to Shareholders

 
GlobeNewswireJune 27, 2018
 
 

LAS VEGAS, June 27, 2018 (GLOBE NEWSWIRE) -- CV Sciences, Inc., (CVSI) (the "Company," "CV Sciences," "our" or "we"), preeminent manufacturer and distributor of the industry-dominating brand of hemp extract products, PlusCBD Oil™, announced today that it has issued a letter to its shareholders, providing an update on the Company’s recent progress and upcoming objectives. 

Highlights of the Letter Include:

  • Summary of its record breaking and profitable first quarter of 2018 which included record revenue, gross profit, cash flow, adjusted EBITDA and net income.
     
    Expansion of the Company’s footprint in the CBD product market with its PlusCBD Oil™ hemp-based CBD products rated #1 in the natural products retailer sales channel.  This market opportunity is forecasted at $2.5 billion by 2022.
     
    Updates on its drug development efforts, its proprietary patent-pending drug candidate (CVSI-007) to treat smokeless tobacco addiction, a $2 billion market opportunity.
     
    Corporate developments that include deleveraging the Company’s balance sheet and positioning for future growth.
     
    Details of CV Sciences’ upcoming annual general meeting (AGM) to be held on August 4, 2018 at the Company’s new San Diego headquarters.
     
    Initiatives for 2018, focusing on operational efficiencies, sales growth, distribution channels, large drug development milestones that include investigational new drug application submission and clinical trials, and uplisting our stock to a major national exchange.

The Company’s Chief Executive Officer, Joseph Dowling, commented, “Our uplist initiative to a major national exchange is an important Company objective. The national exchanges require that a listed company’s stock price trade at certain levels for acceptance. We have included a proposal for shareholder vote at our AGM on August 4, 2018 for a reverse stock split, which has as its sole purpose clearing a pathway for the Company to “uplist” to a major national exchange. The Company will effectuate the reverse split only in connection with an application to uplist to a major exchange, and only if necessary.”  

To read the Letter to Shareholders in full, please visit: https://ir.cvsciences.com

About CV Sciences, Inc.

CV Sciences, Inc. (CVSI) operates two distinct business segments: a drug development division focused on developing and commercializing novel therapeutics utilizing synthetic CBD; and a consumer product division in manufacturing, marketing and selling plant-based CBD products to a range of market sectors. CV Sciences, Inc. has primary offices and facilities in San Diego, California and Las Vegas, Nevada. Additional information is available from OTCMarkets.com or by visiting www.cvsciences.com.

FORWARD-LOOKING DISCLAIMER

This press release may contain certain forward-looking statements and information, as defined within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, and is subject to the Safe Harbor created by those sections. This material contains statements about expected future events and/or financial results that are forward-looking in nature and subject to risks and uncertainties. Such forward-looking statements by definition involve risks, uncertainties.

CONTACT INFORMATION:

Robert Haag
Managing Director
IRTH Communications
CVSI@irthcommunications.com
866-976-4784

 

The Company competes with GW Pharmaceuticals, PLC, Zynerba Pharmaceuticals Inc. and Insys Therapeutics Inc

 

CV Sciences, Inc. Announces Landmark Publication on the Toxicology and Safety Assessment of Base Material of its PlusCBD Oil™ Products

 
GlobeNewswireJune 15, 2018
 
 

LAS VEGAS, June 15, 2018 (GLOBE NEWSWIRE) -- CV Sciences, Inc. (CVSI) (the “Company”, “CV Sciences”, “our” or “we”) announced today the June 7, 2018 publication of the toxicology and safety results of an extract from the base raw materials used in its market leading PlusCBD Oil™ consumer products. The Company contracted respected scientific and regulatory consulting firm, AIBMR Life Sciences, Inc, to conduct the battery of toxicological studies to investigate the safety of oral consumption of the Company’s hemp cannabidiol (CBD) oil and to support a Generally Recognized as Safe (GRAS) Independent Conclusion.

The monumental study entitled, “An Assessment of the Genotoxicity and Subchronic Toxicity of a Subcritical Fluid Extract of the Aerial Parts of Hemp”concluded that the test article was non-mutagenic, non-clastogenic and non-genotoxic. The toxicological assessment is the first known published data of its kind since the 1980 Rosenkrantz et al.’s publication with respect to toxicology data on CBD, Cannabichromene and hashish oil. The battery of GLP/OECD compliant studies is a major contribution in advancement of the science of hemp-derived CBD.

The investment in this toxicological assessment demonstrates CV Sciences’ commitment in furthering the science behind the ingredient. AIBMR’s Chief Scientific Officer, John Endres, ND, comments, “Until today, there have been no comprehensive toxicological safety assessments completed on hemp CBD oil for 38 years. The completion and publication of these safety studies on this ingredient in a peer-reviewed academic journal specializing in toxicology is a monumental step forward in putting competent and reliable science behind a product. The public should applaud this effort as well as the time and expense it required.”

The Company’s Chief Executive Officer, Joseph Dowling, echoed this sentiment. “We are thrilled to advance phytocannabinoid science and are very pleased with the safety results from this landmark study. This is an important milestone in our pursuit of GRAS status,” he remarked. “As an organization, our commitment to safety remains paramount. We look forward to setting the bar for all hemp extract manufacturers in the market and encourage them to conduct similar toxicological assessments on their own base raw materials.”

About CV Sciences, Inc.
CV Sciences, Inc. (CVSI) operates two distinct business segments: a drug development division focused on developing and commercializing novel therapeutics utilizing synthetic CBD; and, a consumer product division focused on manufacturing, marketing and selling plant-based CBD products to a range of market sectors. CV Sciences, Inc. has primary offices and facilities in Las Vegas, Nevada and San Diego, California.  Additional information is available from OTCMarkets.com or by visiting www.cvsciences.com.

Video tour of San Diego Office of CVSI.
https://www.facebook.com/pluscbdoil/videos/1974202205985123/

Cannabis Report
Lithium
CVSI
Current Price
Volume:
Bid Ask Day's Range
  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
PlusOneCoin Top Posts
#17910   Re: Bashers (Vandalayind's) Handbook. jefra1965 08/16/18 10:56:05 AM
PostSubject
#15209  Sticky Note CVSI - CV Sciences Inc - compiled DD ANIA77 07/24/18 01:46:19 PM
#14381  Sticky Note Video tour of San Diego Office of CVSI. ap17 07/02/18 01:13:14 AM
#18010   I am going to ride this bad boy Jsampayo23 08/16/18 05:15:35 PM
#18009   I hate to ruin your peace but I jefra1965 08/16/18 05:08:20 PM
#18008   Your post explains why you have so many Pennyprof 08/16/18 05:07:47 PM
#18007   * * $CVSI Video Chart 08-16-18 * * ClayTrader 08/16/18 05:07:25 PM
#18006   So boys and girls, whats everyone doing? Holding...selling....doubling up...lol Sunblazers 08/16/18 05:06:50 PM
#18005   This is just a digital tea leaf reader. microcappatty 08/16/18 05:00:46 PM
#18004   Vandalay CBD vaseline coming soon. litfaa 08/16/18 04:59:22 PM
#18003   https://walletinvestor.com/stock-forecast/cvsi-stock-prediction Jsampayo23 08/16/18 04:55:03 PM
#18002   The only meaningful thing he can possibly say microcappatty 08/16/18 04:50:17 PM
#18001   Agreed. All one has to do is Natureboy1 08/16/18 04:45:04 PM
#18000   Who really cares what Vandalay writes, excite for MartyTamreau 08/16/18 04:45:01 PM
#17999   All facts my friend and please don't waist jefra1965 08/16/18 04:38:41 PM
#17998   At the end of the day , bye basher Torez 08/16/18 04:32:56 PM
#17997   At the end, you said it, not me. Pennyprof 08/16/18 04:32:09 PM
#17996   Easy too look at your profile. And you Torez 08/16/18 04:30:18 PM
#17995   I think $100 is the top. Natureboy1 08/16/18 04:30:12 PM
#17994   Replace every basher word with pumper and see Pennyprof 08/16/18 04:29:33 PM
#17993   No, I don't think that at all. I DilJam 08/16/18 04:28:15 PM
#17992   Look at the daily chart(aka 1 year). You Pennyprof 08/16/18 04:26:02 PM
#17991   CVSI TTM Powerful Numbers (Trailing 12 Months) jefra1965 08/16/18 04:25:47 PM
#17990   Chart? Where? It has been many of you Torez 08/16/18 04:25:04 PM
#17989   You bought the top! lmao! Pennyprof 08/16/18 04:24:31 PM
#17988   What makes you think that? Looked good to DilJam 08/16/18 04:23:39 PM
#17987   Lol, guess we'll see. Chart is indicating the Pennyprof 08/16/18 04:23:01 PM
#17986   No, you not getting cheeper, this will go Torez 08/16/18 04:20:36 PM
#17985   Ouch! That's rough. It was looking to be DilJam 08/16/18 04:20:27 PM
#17983   Looks like the top is in, time for Pennyprof 08/16/18 04:19:22 PM
#17982   Too funny. Finally got some more funds Natureboy1 08/16/18 04:12:55 PM
#17980   Day trades Torez 08/16/18 04:09:02 PM
#17979   Longs here. Read this re: locking up your playofthedivine 08/16/18 04:05:18 PM
#17978   What happened at the close. Did I miss RLBTrader 08/16/18 04:04:44 PM
#17977   On track with good volume. Price volume rules.. traderjbr 08/16/18 04:04:04 PM
#17976   Well those last two minutes really sucked CashMoneyCarl 08/16/18 04:03:44 PM
#17975   Effing daily traders, hope they will chase it Torez 08/16/18 04:00:25 PM
#17974   Not kidding this time, just heard some talk litfaa 08/16/18 03:58:51 PM
#17973   My posts look like pumping but I'm not vdb_123 08/16/18 03:57:45 PM
#17972   Exactly!! Only the wins, just like any Vegas gambler. ap17 08/16/18 03:54:00 PM
#17971   35k more! dbmich 08/16/18 03:53:30 PM
#17970   33k buy just now! dbmich 08/16/18 03:49:53 PM
#17969   Mate: you're misinterpreting my post. I said "possible" playofthedivine 08/16/18 03:48:00 PM
#17968   I know there's more, but for a future playofthedivine 08/16/18 03:46:06 PM
#17967   playofthedivine: litfaa 08/16/18 03:43:01 PM
#17965   Yay everyone is so happy. Anyway. What’s Rookie211 08/16/18 03:36:44 PM
#17964   $20 ? My target is $50 by next playofthedivine 08/16/18 03:35:46 PM
#17963   Thats my sell limit Torez 08/16/18 03:24:08 PM
#17962   agreed! $20 may actually come this year with ap17 08/16/18 03:24:02 PM
#17961   $20 ? My target is $50 by next vdb_123 08/16/18 03:19:24 PM
#17960   $6 is definitely a possibility, as for the ap17 08/16/18 03:16:55 PM
#17959   Panic buys coming in for tomorrow Laszlo1 08/16/18 03:16:34 PM
#17958   Could be brought down at the end of Torez 08/16/18 03:15:04 PM
PostSubject